Medicating for mental health

Weight gain and Type 2 diabetes are potential side effects in people taking a common medication to treat mental illness. Now a new University of Guelph study has revealed that a single bout of intense exercise performed right before taking a dose of olanzapine could be a way to prevent these side effects.

Published in the journal Scientific Reports, the study investigated how a single bout of intense exercise could reduce olanzapine-induced hyperglycemia in male mice. Olanzapine is an anti-psychotic medication that is used in the treatment of schizophrenia and causes blood sugar levels to rise with each dose taken.

"Acute repeated spikes in blood sugar that you see with each dose of this drug have long-term impacts - and can predispose patients to the development of insulin-resistance Type 2 diabetes and cardiovascular disease," said David Wright, associate professor in the Department of Human Health and Nutritional Sciences and corresponding author of the paper.

Patients generally take such drugs as olanzapine over a long period, meaning that they may have serious impacts on patients' overall health, added Wright.

"If you look at the average life expectancy of an individual with schizophrenia versus someone in the general population, it's a 20-year gap. If we can reduce the side effects associated with blood glucose levels, hopefully we can improve life expectancy and the overall quality of life."

In their study, Wright and PhD student Laura Castellani exercised mice by having them run until they reached exhaustion before giving them a dose of olanzapine. The researchers discovered the exercise prevented the rise in blood glucose levels that typically occurs when taking the medication.

However, the researchers found it must be intense exercise. When they repeated the tests with only moderate exercise similar to a fast jog, blood glucose levels still rose in mice because of the medication.

Although these findings are encouraging, Wright says there are challenges.

"Translating these findings to humans will be difficult, especially considering that patients taking anti-psychotics have a very low level of exercise adherence," he said. "The next step is to see if we can identify the pathways that are activated during exercise so that we can perhaps target them pharmacologically or nutritionally."

While clinicians have been looking at different ways to prevent higher blood glucose levels by prescribing anti-diabetic drugs, Wright said his lab is interested in exercise physiology and trying to figure out how exercise can improve glucose homeostasis.

"Cardiovascular disease is the leading cause of death in individuals that have schizophrenia," said Wright. "And obviously not everything can be attributed to the metabolic effects of these drugs. But if we can look at the big picture and reduce these side effects, hopefully life expectancy and quality of life can be improved because once you go on these drugs you can't really go off of them."

Laura N Castellani, Willem T Peppler, Paula M Miotto, Natasha Bush, David C. Wright.
Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL/6J Mice.
Scientific Reportsvolume 8, Article number: 772 (2018). doi: 10.1038/s41598-018-19260-x.

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...